Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Sera Prognostics, Inc. Chief Executive Officer Zhenya Lindgardt reported selling a total of 25,612 shares of Class A common stock in two open-market transactions on March 10 and March 11, 2026 at weighted average prices of $1.90 and $2.04 per share.
According to the disclosure, these sales were mandated "sell to cover" transactions to satisfy tax withholding obligations from vesting restricted stock units, and are not discretionary trades. After the transactions, Lindgardt directly holds 738,314 shares. The trades were executed as block trades within disclosed price ranges.
Sera Prognostics Chief Data Officer Paul Kearney reported an open-market sale of 1,396 shares of Class A Common Stock at a weighted average price of $2.04 per share. According to the disclosure, the shares were sold solely to cover tax withholding on vested RSUs under a mandatory “sell to cover” arrangement, and were not a discretionary trade. After this transaction, Kearney directly holds 163,961 shares of Sera Prognostics stock.
SERA PROGNOSTICS, INC. General Counsel Benjamin Jackson reported a small mandated share sale related to equity compensation. On March 11, 2026, he sold 1,027 shares of Class A common stock in a block trade at a weighted average price of $2.04 per share.
According to the disclosure, the sale was executed solely to cover tax withholding obligations triggered by the vesting of restricted stock units under a required “sell to cover” arrangement, meaning it was not a discretionary trade. After this transaction, Jackson directly holds 114,720 shares of Sera Prognostics common stock.
SERA PROGNOSTICS, INC. Chief Information Officer Robert Gardner reported an open-market sale of 716 shares of Class A common stock at a weighted average price of $2.04 per share. This reduced his direct holdings to 76,712 shares.
According to the footnotes, the sale was mandated to cover tax withholding obligations tied to vesting restricted stock units under a required “sell to cover” arrangement, and is described as a non-discretionary transaction rather than an elective share sale. The shares were sold as part of a block trade at prices ranging from $1.90 to $2.30 per share.
Sera Prognostics Chief Scientific Officer John J. Boniface reported an open-market sale of 1,517 shares of Class A common stock at a weighted average price of $2.04 per share. The sale was used to cover tax withholding obligations related to vesting restricted stock units and was mandated by the company’s sell-to-cover policy, not a discretionary trade. After the transaction, he directly holds 145,842 shares. The shares were sold in a block trade at prices ranging from $1.90 to $2.30 per share.
Sera Prognostics Chief Financial Officer Austin Aerts reported mandatory share sales tied to tax withholding on vested RSUs. On March 10 and March 11, he sold a total of 7,088 shares of Class A common stock in open-market block trades to cover tax obligations.
The sales occurred at weighted average prices of $1.90 and $2.04 per share, within disclosed ranges from $1.77 to $2.36. After these transactions, Aerts directly held 264,452 shares of Sera Prognostics common stock. The filing states these were not discretionary trades.
Insider filed a Form 144 to sell Class A Common shares. The form lists a proposed sale of 2,973 shares to be effected through Morgan Stanley Smith Barney LLC on 03/11/2026. The filing also records prior dispositions of 4,155 shares on 12/10/2025 and 22,639 shares on 03/10/2026.
SERA filed a Form 144 reporting a proposed sale of Class A Common stock tied to restricted stock unit vesting with an effective date of 03/11/2026. The filing lists recent dispositions by Paul Kearney on 12/10/2025 and 03/09/2026.
SERA reported insider sale activity via a Form 144 notice. The filing lists sales by Benjamin Jackson of 892 shares on 12/10/2025 and 3,119 shares on 03/09/2026. The filing also lists 1,027 Class A shares tied to restricted stock unit vesting with a 03/11/2026 vesting date.
Robert Harrison reports proposed resale of 716 shares of Class A Common associated with Restricted Stock Unit vesting on 03/11/2026.
The filing also lists completed open‑market sales by Robert Harrison: 616 shares on 12/10/2025, 2,000 shares on 12/30/2025, 2,000 shares on 01/27/2026, 2,000 shares on 02/24/2026, and 3,360 shares on 03/09/2026.